European Businesses Neglect to Measure Value of Outsourcing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

European Businesses Neglect to Measure Value of Outsourcing


ePT--the Electronic Newsletter of Pharmaceutical Technology

Only 43% of European chief financial officers (CFOs) and chief information officers (CIOs) have tried to calculate the impact of outsourcing on their company, and of those that have tried, only 1 in 5 are confident about their calculations, according to a study by Cognizant, a global business technology company based in Teaneck, New Jersey. Meanwhile, more than one-third (37%) of those interviewed have not attempted to measure their return on investment from outsourcing, and 20% don't know whether they have tried to measure such a figure.

"Outsourcing has clear, long- and short-term benefits for businesses, but the research shows that many companies could be missing out by failing to adequately measure outsourcing's impact," said Sanjiv Gossain, vice-president and managing director for the UK and Ireland at Cognizant, in a company statement.

The survey was conducted in association with the United Kingdom’s Warwick Business School at Europe's largest companies between April and July of this year. According to Cognizant, outsourcing is an integral part of all pharmaceutical operations and more than $42 billion was spent on outsourcing deals in 2008.

However, many companies do not understand the real value of outsourcing. Measurement methods cited by CIOs and CFOs in the Cognizant survey were vague. Some comments, for example, included “manual calculation,” “You know what it costs, but you don't really know the value,” and "The accountants will use some formula for calculating return on investment."

"The report flags a critical gap in managerial knowledge, and some businesses clearly have to do better in justifying their significant outsourcing spend to the board," said Julia Kotlarsky, associate professor of information systems at Warwick, in the statement. "Outsourcers need to work closely with the CIO, CFO, and their teams to reduce the maintenance budgets and apply them to the proactive, revenue-generating activities the business demands to maximize the long-term business value of outsourcing engagements."

Stephanie Sutton is an assistant editor with PharmTech Europe.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles
Greater adoption of continuous manufacturing
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
The rise of biologic-based drugs in commercial product portfolios and pipelines
Greater adoption of the preferred provider model in outsourcing
Fuller adoption of quality by design principles
22%
Greater adoption of continuous manufacturing
7%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
35%
The rise of biologic-based drugs in commercial product portfolios and pipelines
30%
Greater adoption of the preferred provider model in outsourcing
7%
View Results
Jim MillerOutsourcing OutlookJim Miller Channeling Steve Jobs
Patricia Van ArnumIngredients InsiderPatricia Van ArnumSeeking Chemocatalytic and Biocatalytic Solutions
Nathan JessopIndustry InsiderNathan Jessop Taxing Times for French Pharma
Lynn D. TorbeckStatistical Solutions Lynn D. TorbeckRepresentative Sampling
Report on Recent and Upcoming Single-Use Meetings
ICH Q11 Reaches Harmonization, Implementation is Next
Digital Signatures Growing as a Result of Part 11
Single-Cell Genomics Advancing Molecular Biology
Putting FDA’s “Process Validation” Guidance into Action
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here